SWK Holdings Corp (SWKHL)
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Sector: Miscellaneous Business Credit Institution
Industry: Financial - Credit Services
SWK Holdings Corporation 9.00% Senior Notes due 2027
No splits on record
Nothing in SWKHL's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $41.46M |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $1.55M |
| Selling, General, and Administrative | $14.76M |
| Other | $0 |
| Total Operating Expenses | $16.31M |
| Operating Income (EBIT) | $20.27M |
| Operating Margin | 48.9% |
| Interest Expense | $4.8M |
| Interest Income | $0 |
| Other Income (Expense) | -$159K |
| Income Before Tax (EBT) | $20.12M |
| Income Tax Expense | $22.65M |
| Net Income | -$2.53M |
| Net Income Margin | -6.1% |
| Supplementary Data | |
| EPS | -0.21 |
| Diluted EPS | -0.21 |
| Weighted Average OS | 12.16M |
| EBITDA | $24.95M |
| EBITDA Margin | 60.2% |
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $42.76M |
| Short-Term Investments | $0 |
| Cash and Short-Term Investments | $42.76M |
| Accounts Receivable | $3.86M |
| Inventory | $0 |
| Other Current Assets | $163K |
| Total Current Assets | $46.79M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $0 |
| Goodwill | $0 |
| Intangible Assets | $0 |
| Long-Term Investments | $184K |
| Deferred Tax Assets | $912K |
| Other Long-Term Assets | $224.54M |
| Total Long-Term Assets | $225.64M |
| Other Assets | $0 |
| Total Assets | $272.42M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $0 |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $4.97M |
| Total Current Liabilities | $4.97M |
| Long-Term Liabilities | |
| Long-Term Debt | $32.11M |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $240K |
| Total Long-Term Liabilities | $32.35M |
| Other Liabilities | $0 |
| Total Liabilities | $37.32M |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $12K |
| Retained Earnings | -$4.18B |
| Comprehensive Income & Other | $0 |
| Other Stockholders' Equity | $4.42B |
| Total Equity | $235.1M |
| Minority Interest | $0 |
| Total Liabilities and Equity | $272.42M |
| Supplementary Data | |
| Total Debt | $32.11M |
| Net Debt | -$10.65M |
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$2.53M |
| Depreciation & Amortization | $143K |
| Deferred Income Tax | $0 |
| Stock-Based Compensation | $1.18M |
| Changes in Working Capital: | |
| Accounts Receivable | $1.93M |
| Inventory | $314K |
| Accounts Payable | $1.59M |
| Other Working Capital | $0 |
| Total Working Capital Change | $0 |
| Other Non-Cash Items | $28.5M |
| Net Cash from Operating | $27.29M |
| Investing Activities | |
| Capital Expenditures | $0 |
| Acquisitions | $0 |
| Purchases of Investments | $0 |
| Sales of Investments | $0 |
| Other Investing Activities | $0 |
| Net Cash from Investing | $0 |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $0 |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | $0 |
| Net Cash from Financing | $0 |
| Forex Effect | $0 |
| Net Change in Cash | $0 |
| Supplementary Data | |
| Operating Cash Flow | $27.29M |
| Capital Expenditure | $0 |
| Free Cash Flow | $27.29M |
| Cash at Beginning | $0 |
| Cash at End | $0 |